Universal screening for a condition we can’t target specifically? 🤔

The new 2026 ACC/AHA Dyslipidemia Guideline issued a Class 1 Recommendation for every adult in the US to get their Lipoprotein(a) measured once in a lifetime.But here is the catch: if you find it elevated, the guideline’s core recommendation is simply to optimize modifiable risk factors—the exact same care we should already be providing.With no completed outcomes trials yet proving that lowering Lp(a) reduces major cardiovascular events, this leaves primary care clinicians in a fascinating spot. Is this universal screening push brilliant proactive medicine, or is it market priming for an incoming class of therapeutics?In Part 3 of our critical appraisal series, we look at 30 years of data from the landmark Women's Health Study to separate the medicine from the marketing.📺 Watch the full appraisal here: www.youtube.com/@DispenseAsWritten#EvidenceBasedMedicine #PrimaryCare #InternalMedicine #MedEd #Cardiology #LpaScreening